Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486869 · ClinicalTrials.gov registry record · Phase 2
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
A Phase 2 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT07486869: Clinical Trial Phase 2 study, sponsored by University of Miami.
NCT07486869 is a Phase 2 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07486869, a Phase 2 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Primary Outcome
Supplemental oxygen requirement assessed as the oxygen flow rate (reported in liters per minute \[L/min\]) while the participant is at rest and, when feasible, while the participant is ambulating during the 6-Minute Walk Test (6MWT). Values are compared with baseline to assess change over time.
Interventions
- DRUG Emapalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What is known before NCT07486869 opens enrollment
NCT07486869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Emapalumab is the first listed.
NCT07486869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07486869 about?
NCT07486869 is a clinical study titled "Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study". This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage...
What is the current status of trial NCT07486869?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2026-07. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07486869?
The interventions under investigation include: Emapalumab (DRUG).
Who is sponsoring clinical trial NCT07486869?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07486869's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia